Carter HB - Search Results

1

Complications after prostate biopsy: data from SEER-Medicare.

Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Loeb S, et al. Among authors: carter hb. J Urol. 2011 Nov;186(5):1830-4. doi: 10.1016/j.juro.2011.06.057. Epub 2011 Sep 23. J Urol. 2011. PMID: 21944136

2

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Carter HB, Walsh PC, Landis P, Epstein JI. Carter HB, et al. J Urol. 2002 Mar;167(3):1231-4. J Urol. 2002. PMID: 11832703

3

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

Fang J, Metter EJ, Landis P, Carter HB. Fang J, et al. Among authors: carter hb. Urology. 2002 Jun;59(6):889-93; discussion 893-4. doi: 10.1016/s0090-4295(02)01646-1. Urology. 2002. PMID: 12031375

4

Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging.

Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ, Platz EA; Baltimore Longitudinal Study of Aging. Berndt SI, et al. Among authors: carter hb. Urology. 2002 Dec;60(6):1118-23. doi: 10.1016/s0090-4295(02)01991-x. Urology. 2002. PMID: 12475694

5

Informed consent for prostate-specific antigen screening.

Carter HB. Carter HB. Urology. 2003 Jan;61(1):13-4. doi: 10.1016/s0090-4295(02)02009-5. Urology. 2003. PMID: 12559256 No abstract available.

6

Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States).

Hsieh LJ, Carter HB, Landis PK, Tucker KL, Metter EJ, Newschaffer CJ, Platz EA. Hsieh LJ, et al. Among authors: carter hb. Urology. 2003 Feb;61(2):297-301. doi: 10.1016/s0090-4295(02)02120-9. Urology. 2003. PMID: 12597934

7

Expectant management of localized prostate cancer.

Khan MA, Partin AW, Carter HB. Khan MA, et al. Among authors: carter hb. Urology. 2003 Nov;62(5):793-9. doi: 10.1016/s0090-4295(03)00653-8. Urology. 2003. PMID: 14624896 Review. No abstract available.

8

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Khan MA, et al. Among authors: carter hb. J Urol. 2003 Dec;170(6 Pt 1):2274-8. doi: 10.1097/01.ju.0000097124.21878.6b. J Urol. 2003. PMID: 14634395

9

Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging.

Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA. Hubbard JS, et al. Among authors: carter hb. Urology. 2004 Feb;63(2):253-8. doi: 10.1016/j.urology.2003.09.060. Urology. 2004. PMID: 14972466

10

Update on watchful waiting for prostate cancer.

Allaf ME, Carter HB. Allaf ME, et al. Among authors: carter hb. Curr Opin Urol. 2004 May;14(3):171-5. doi: 10.1097/00042307-200405000-00006. Curr Opin Urol. 2004. PMID: 15069308 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results